Protective effect of guggulsterone against cardiomyocyte injury induced by doxorubicin in vitro

BMC Complementary and Alternative Medicine

Volumn 12, Issue , 2012, Pages

  Wang, Wen Ching ^a   Uen, Yih Huei ^a,b   Chang, Ming Long ^c   Cheah, Khoot Peng ^c   Li, Joe Sharg ^c   Yu, Wen Yu ^c   Lee, Kock Chee ^c   Choy, Cheuk Sing ^d,e   Hu, Chien Ming ^c,e  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d Bali Mental Hospital   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cardiotoxicity; Cytokines; Doxorubicin; Guggulsterone; Reactive oxygen species

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; CASPASE 3; CYTOCHROME C; DOXORUBICIN; GUGGULSTERONE; LACTATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL DAMAGE; CELL DEATH; CELL PROTECTION; CELL VIABILITY; CONCENTRATION (PARAMETERS); DRUG CYTOTOXICITY; EMBRYO; ENZYME ACTIVITY; ENZYME RELEASE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IN VITRO STUDY; INTRACELLULAR SPACE; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; RAT; WESTERN BLOTTING;

EID: 84865328321     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-12-138     Document Type: Article

References (42)

1. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998, 339:900-905. 10.1056/NEJM199809243391307, 9744975.
2. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56:185-229. 10.1124/pr.56.2.6, 15169927.
3. Yeh E, Tong A, Lenihan D, Yusuf S, Swafford J, Champion C, Durand J, Gibbs H, Zafarmand A, Ewer M. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004, 109:3122-3131. 10.1161/01.CIR.0000133187.74800.B9, 15226229.
4. Wallace KB. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 2003, 93:105-115. 10.1034/j.1600-0773.2003.930301.x, 12969434.
5. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007, 49:330-352. 10.1016/j.pcad.2006.10.002, 17329180.
6. Neilan T, Blake S, Ichinose F, Raher M, Buys E, Jassal D, Furutani E, Perez-Sanz T, Graveline A, Janssens S, et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007, 116:506-514. 10.1161/CIRCULATIONAHA.106.652339, 17638931.
7. Menna P, Minotti G, Salvatorelli E. In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity. Cell Biol Toxicol 2007, 23:49-62. 10.1007/s10565-006-0143-8, 17031515.
8. Elbl L, Hrstkova H, Tomaskova I, Michalek J. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up. Support Care Cancer 2006, 14:128-136. 10.1007/s00520-005-0858-8, 16034614.
9. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005, 131:561-578. 10.1111/j.1365-2141.2005.05759.x, 16351632.
10. Urizar NL, Moore DD. Gugulipid: a natural cholesterol-lowering agent. Annu Rev Nutr 2003, 23:303-313. 10.1146/annurev.nutr.23.011702.073102, 12626688.
11. Shen T, Lou HX. Bioactive constituents of myrrh and frankincense, two simultaneously prescribed gum resins in Chinese traditional medicine. Chem Biodivers 2008, 5:540-553. 10.1002/cbdv.200890051, 18421746.
12. Bhatta RS, Kumar D, Chhonker YS, Jain GK. Simultaneous estimation of E- and Z-isomers of guggulsterone in rabbit plasma using liquid chromatography tandem mass spectrometry and its application to pharmacokinetic study. Biomed Chromatogr 2011, 25:1054-1060. 10.1002/bmc.1574, 21268049.
13. Patil VD, Nayak UR, Dev S. Chemistry of Ayurvedic crude drugs-I : Guggulu (resin from Commiphora mukul)-1: Steroidal constituents. Tetrahedron 1972, 28:2341-2352.
14. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 2002, 296:1703-1706. 10.1126/science.1072891, 11988537.
15. Wu J, Xia C, Meier J, Li S, Hu X, Lala DS. The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor. Mol Endocrinol 2002, 16:1590-1597. 10.1210/me.16.7.1590, 12089353.
16. Deng R. Therapeutic effects of guggul and its constituent guggulsterone: Cardiovascular benefits. Cardiovasc Drug Rev 2007, 25:375-390.
17. Meselhy MR. Inhibition of LPS-induced NO production by the oleogum resin of Commiphora wightii and its constituents. Phytochemistry 2003, 62:213-218. 10.1016/S0031-9422(02)00388-6, 12482459.
18. Shishodia S, Aggarwal BB. Guggulsterone inhibits NF-κB and IκBα kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem 2004, 279:47148-47158. 10.1074/jbc.M408093200, 15322087.
19. Kaul S, Kapoor N. Reversal of changes of lipid peroxide, xanthine oxidase and superoxide dismutase by cardio-protective drugs in isoproterenol induced myocardial necrosis in rats. Indian J Exp Biol 1989, 27:625-627.
20. Han X, Ren D, Fan P, Shen T, Lou H. Protective effects of naringenin-7-O-glucoside on doxorubicininduced apoptosis in H9C2 cells. Eur J Pharmacol 2008, 581:47-53. 10.1016/j.ejphar.2007.11.048, 18154951.
21. Zuckerbraun HL, Babich H, May R, Sinensky MC. Triclosan: cytotoxicity, mode of action, and induction of apoptosis in human gingival cells in vitro. Eur J Oral Sci 1998, 106:628-636. 10.1046/j.0909-8836.1998.eos106204.x, 9584909.
22. Wang CC, Choy CS, Liu YH, Cheah KP, Li JS, Wang JTJ, Yu WY, Lin CW, Cheng HW, Hu CM. Protective effect of dried safflower petal aqueous extracts and its main constituent, carthamus yellow, against lipopolysaccharide (LPS)-induced inflammation in RAW264.7 macrophage. J Sci Food Agric 2011, 91:218-225. 10.1002/jsfa.4172, 20848677.
23. Choy CS, Cheah KP, Chiou HY, Li JS, Liu YH, Yong SF, Chiu WT, Liao JW, Hu CM. Induction of hepatotoxicity by sanguinarine is associated with oxidation of protein thiols and disturbance of mitochondrial respiration. J Appl Toxicol 2008, 28:945-956.
24. Hu CM, Li JS, Cheah KP, Lin CW, Yu WY, Chang ML, Yeh GC, Chen SH, Cheng HW, Choy CS. Effect of Sanguis draconis (a dragon's blood resin) on streptozotocin- and cytokine-induced β-cell damage, in vitro and in vivo. Diabetes Res Clin Pract 2011, 94:417-425. 10.1016/j.diabres.2011.08.014, 21899910.
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254. 10.1016/0003-2697(76)90527-3, 942051.
26. Fukuda M, Tsuchihashi Y, Takamatsu T, Nakanishi K, Fujita S. Fluorescence fading and stabilization in cytofluorometry. Histochemistry 1980, 65:269-276. 10.1007/BF00493176, 6154676.
27. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiomyopathy. Circulation 2005, 111:1601-1610. 10.1161/01.CIR.0000160359.49478.C2, 15811867.
28. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, Factor SM, Shirani J, Armstrong RC, Kitsis RN. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003, 111:1497-1504. 155051, 12750399.
29. Xin H, Liu XH, Zhu YZ. Herba leonurine attenuates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells. Eur J Pharmacol 2009, 612:75-79. 10.1016/j.ejphar.2009.03.067, 19356731.
30. Vidarsson H, Hyllner J, Sartipy P. Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications. Stem Cell Rev 2010, 6:108-120. 10.1007/s12015-010-9113-x, 20091143.
31. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 2006, 41:389-405. 10.1016/j.yjmcc.2006.06.009, 16879835.
32. Liu Z, Song XD, Xin Y, Wang XJ, Yu H, Bai YY, Liu JH, Zhang CN, Hui RT. Protective effect of chrysoeriol against doxorubicin-induced cardiotoxicity in vitro. Chin Med J (Engl) 2009, 122:2652-2656.
33. Li K, Sung RY, Huang WZ, Yang M, Pong NH, Lee SM, Chan WY, Zhao H, To MY, Fok TE, et al. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 2006, 113:2211-2220. 10.1161/CIRCULATIONAHA.105.560250, 16651473.
34. Zhang YW, Shi J, Li YJ, Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp 2009, 57:435-445.
35. Bast A, Haenen GR, Bruynzeel AM, Van der Vijgh WJ. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials. Cardiovasc Toxicol 2007, 7:154-159. 10.1007/s12012-007-0018-0, 17652822.
36. Hosseinzadeh L, Behravan J, Mosaffa F, Bahrami G, Bahrami A, Karimi G. Curcumin potentiates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells through generation of reactive oxygen species. Food Chem Toxicol 2011, 49:1102-1109. 10.1016/j.fct.2011.01.021, 21295102.
37. Kim DS, Woo ER, Chae SW, Ha KC, Lee GH, Hong ST, Kwon DY, Kim MS, Jung YK, Kim HM, et al. Plantainoside D protects adriamycin-induced apoptosis in H9c2 cardiac muscle cells via the inhibition of ROS generation and NF-κB activation. Life Sci 2007, 80:314-323. 10.1016/j.lfs.2006.09.019, 17034819.
38. Wang H, Joseph JA. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic Biol Med 1999, 27:612-616. 10.1016/S0891-5849(99)00107-0, 10490282.
39. Eltze T, Boer R, Wagner T, Weinbrenner S, McDonald MC, Thiemermann C, Bürkle A, Klein T. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors. Mol Pharmacol 2008, 74:1587-1598. 10.1124/mol.108.048751, 18809672.
40. Aggeli IK, Beis I, Gaitanaki C. Oxidative stress and calpain inhibition induce alpha B-crystallin phosphorylation via p38-MAPK and calcium signalling pathways in H9c2 cells. Cell Signal 2008, 20:1292-1302. 10.1016/j.cellsig.2008.02.019, 18420382.
41. Sugioka R, Shimizu S, Funatsu T, Tamagawa H, Sawa Y, Kawakami T, Tsujimoto Y. BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo. Oncogene 2003, 22:8432-8440. 10.1038/sj.onc.1207180, 14627984.
42. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 2002, 234/235:119-124.